Filing Flows › Insmed (INSM) › Q2 2026 › vs Q2 2025
Insmed (INSM) Q2 2026 vs Q2 2025 (year over year)
Insmed's revenue rose $318M (+296%) from $107M in Q2 2025 to $425M in Q2 2026. The biggest changes: BRINSUPRI +$309M (—); ARIKAYCE +$8.9M (+8%).
Insmed, Q2 2026: revenue $425M (+296% year over year), operating margin -0.4%, net loss $13.2M, operating cash flow −$88.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| BRINSUPRI | $309M | $0 | $309M | — |
| ARIKAYCE | $116M | $107M | $8.9M | +8% |
| Revenue | $425M | $107M | $318M | +296% |
| Net loss | $13.2M | $322M | −$308M | -96% |
| Costs & expenses | $439M | $429M | $9.6M | +2% |
| Operating costs | $427M | $420M | $6.7M | +2% |
| Interest & other, net | $9.8M | $7.6M | $2.3M | +30% |
| Income tax | $1.9M | $1.2M | $626K | +50% |
| Operating cash sources | $135M | $252M | −$117M | -46% |
| Depreciation & amortization | $5.3M | $3.7M | $1.5M | +40% |
| Share-based compensation | $41.3M | $43.0M | −$1.7M | -4% |
| Cash used in operations | $88.8M | $206M | −$117M | -57% |
| Net loss absorbed | $13.2M | $322M | −$308M | -96% |
| Working capital & other | $122M | −$69.4M | $191M | — |
Questions
How much did Insmed's revenue grow year over year in Q2 2026?
Insmed's revenue rose $318M (+296%) from $107M in Q2 2025 to $425M in Q2 2026.
What drove Insmed's revenue change in Q2 2026?
BRINSUPRI +$309M (—); ARIKAYCE +$8.9M (+8%).